The board of directors of JBM (Healthcare) Limited announced that Dr. Chu Ka Wing has resigned as an executive director of the Company, the president of the proprietary Chinese medicine business of the Group and an authorised representative of the Company for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited with effect from 19 March 2022 in order to devote more time for his family and his personal development. Dr. Chu has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board announced that Miss Au Man Yee, Teresa has resigned as the company secretary of the Company, and Mr. Lam Kau Lap has been appointed, as the company secretary of the Company with effect from 19 March 2022.

Ms. Au has confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company. Mr. Lam Kau Lap is the Vice President of Finance of the Company and is mainly responsible for the management of the finance and accounting and company secretarial functions of the Group. He has over 10 years of experience in auditing, accounting and finance fields.

He joined the group of Jacobson Pharma Corporation Limited, being a controlling shareholder of the Company, in January 2015 as the finance manager, and was later promoted to deputy financial controller in May 2019. He was re-designated as the Group Financial Controller of the Group in July 2020 and resigned in April 2021. He then re-joined the Group in February 2022.

The Board further announced that Mr. Lam, the Vice President of Finance and Company Secretary of the Company, has been appointed as an Authorised Representative of the Company to fill the vacancy arising from the resignation of Dr. Chu with effect from 19 March 2022.